Nextstellis 28 Day Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Nextstellis 28 Day are increasingly reporting difficulty filling their prescriptions at local pharmacies. While no national FDA shortage has been declared, the combination of brand-only status, inconsistent pharmacy stocking, and evolving insurance formularies creates real-world access barriers that prescribers must navigate. This guide summarizes what you need to know to support your patients.

Current Availability Status (2026)

As of 2026, Nextstellis is not on the FDA official drug shortage list and Mayne Pharma has not announced manufacturing disruptions. However, the following factors create a de facto availability challenge:

• Brand-exclusive market: No FDA-approved generic exists. Patent protection is expected to last until at least 2036, and Nextstellis's last exclusivity period is expiring around 2026, which may eventually open the door to generic applications, but no generic is currently in the pipeline.
• Selective pharmacy stocking: Because Nextstellis carries a high retail price (~$240–$300/pack) and relatively lower prescribing volume compared to generic contraceptives, many pharmacies do not keep it as a routine stock item.
• Insurance formulary variability: While the ACA mandates coverage of FDA-approved contraceptive methods without cost-sharing, plans may impose prior authorization requirements or step-therapy protocols for newer brand-name drugs, delaying access.

Clinical Rationale for Prescribing Nextstellis

Understanding why a patient was specifically prescribed Nextstellis is essential before considering any substitution. Key clinical differentiators include:

• Estetrol's selective estrogen receptor activity: E4 selectively binds nuclear ERα and antagonizes membrane ERα, producing different tissue effects than ethinyl estradiol. Phase III data demonstrated lower SHBG increases, more neutral effects on liver enzymes, and a favorable lipid profile compared to EE-containing comparators.
• Anti-androgenic and anti-mineralocorticoid progestin: Drospirenone (3 mg) is a spironolactone analogue providing anti-androgenic activity, which can benefit patients with acne or hirsutism, and anti-mineralocorticoid activity, reducing estrogen-associated fluid retention.
• Predictable bleeding profile: Phase III studies showed low rates of unscheduled bleeding, with unscheduled bleeding/spotting decreasing from 30.3% at Cycle 1 to 17.4% by Cycle 12.

Strategies to Improve Access for Your Patients

When patients report difficulty finding Nextstellis, consider the following approaches:

1. Send the prescription to a hospital-affiliated or high-volume outpatient pharmacy. These are more likely to maintain Nextstellis inventory or can order it the same day.
2. Direct patients toward mail-order pharmacies. Writing a 90-day supply prescription reduces the fill frequency and often results in better copay rates through the patient's plan.
3. Submit prior authorization proactively. If your practice sees frequent PA requests for Nextstellis, develop a template letter documenting the clinical rationale (E4 tolerability benefits, drospirenone's anti-androgenic properties, prior EE failures or intolerances).
4. Refer uninsured or undercovered patients to the Mayne Pharma savings card. Eligible uninsured patients can pay as little as $25/month; insured patients with coverage may pay $0. The savings program is available at nextstellis.com/savings.
5. Recommend medfinder to patients. medfinder calls local pharmacies on the patient's behalf to find which ones have Nextstellis in stock, then texts the patient the results.

Clinically Appropriate Alternatives When Nextstellis Is Unavailable

If a therapeutic substitution is clinically appropriate, consider:

• Drospirenone 3 mg / Ethinyl estradiol 0.02 mg (generic Yaz): Shares the same progestin as Nextstellis; widely available generically. Most appropriate when drospirenone's anti-androgenic properties are a priority.
• Slynd (drospirenone 4 mg, progestin-only): Appropriate for patients who cannot use estrogen. Contains higher-dose drospirenone without the estrogen component.
• Lo Loestrin Fe (norethindrone 1 mg / EE 10 mcg): Lowest-EE oral COC available; may suit patients where minimizing estrogen exposure is a goal.

Important Prescribing Reminders

• Nextstellis carries a boxed warning: contraindicated in females ≥35 years who smoke.
• Efficacy may be reduced in patients with BMI ≥30 kg/m²; safety has not been established at BMI ≥35 kg/m².
• Monitor potassium in patients on ACE inhibitors, ARBs, potassium-sparing diuretics, or NSAIDs — drospirenone has anti-mineralocorticoid activity and may increase hyperkalemia risk.
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) may reduce Nextstellis efficacy; advise backup contraception during and up to 28 days after use.

The Bottom Line for Providers

Nextstellis availability in 2026 is uneven but manageable with the right prescribing workflow. Proactive prior authorization, directing patients to mail-order pharmacies, and recommending tools like medfinder can significantly reduce access barriers. See our companion article, How to Help Your Patients Find Nextstellis in Stock, for additional provider workflows.